| Phase 4 |
| NCT07600164 |
Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer |
HER2 + Breast Cancer |
Not Yet Recruiting |
| Phase 3 |
| NCT07207070 |
A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy… |
Breast Cancer |
Recruiting |
| NCT07615751 |
Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in… |
Breast Cancer |
Recruiting |
| NCT07528716 |
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy |
Breast Cancer |
Not Yet Recruiting |
| Phase 2/3 |
| NCT04290793 |
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by… |
Breast Cancer |
Active, Not Recruiting |
| Phase 2 |
| NCT07340398 |
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin… |
HER2-positive Early Breast Cancer |
Recruiting |
| NCT07393425 |
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer |
HER2 + Breast Cancer |
Recruiting |
| NCT07335081 |
ctDNA in HER2+ EBC Neoadjuvant Treatment |
Breast Cancer |
Recruiting |
| NCT05769010 |
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases |
Metastatic Breast Cancer |
Recruiting |
| NCT07492394 |
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer |
Breast Cancer |
Recruiting |
| NCT06563999 |
Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare… |
Lung Cancer Stage III |
Recruiting |
| NCT07581834 |
Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR… |
Breast Diseases |
Recruiting |
| NCT05582499 |
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study… |
Breast Neoplasm |
Recruiting |
| NCT07610720 |
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive… |
Advanced/Metastatic Breast Cancer |
Recruiting |
| NCT07307287 |
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced… |
SHR-A1811 |
Not Yet Recruiting |
| NCT04872985 |
Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer |
Breast Cancer |
Active, Not Recruiting |
| NCT07417241 |
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast… |
Breast Cancer |
Not Yet Recruiting |
| NCT06650748 |
Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant… |
Breast Cancer |
Enrolling by Invitation |
| NCT07539753 |
Brain Radiotherapy Combined With Dalpiciclib and Endocrine Therapy in… |
Breast Cancer |
Not Yet Recruiting |
| NCT07618923 |
Neoadjuvant Dalpiciclib + AI → SHR-A1811 for HR+/HER2-Low Breast Cancer |
Breast Cancer |
Not Yet Recruiting |
| Not specified |
| NCT06301438 |
Dalpiciclib in HR+/HER2- ABC |
Advanced Breast Cancer |
Recruiting |
| NCT07470203 |
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in… |
HER2-positive Breast Cancer |
Not Yet Recruiting |
| NCT06495541 |
The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2… |
Breast Cancer |
Not Yet Recruiting |